Evotec And Bristol Myers Squibb Enter Exclusive Global Licence Agreement For Selected Programmes Developed And Progressed In The Collaboration
Portfolio Pulse from Benzinga Newsdesk
Evotec and Bristol Myers Squibb have entered into an exclusive global license agreement for selected programs developed and progressed in their collaboration.
July 11, 2023 | 6:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb has entered into an exclusive global license agreement with Evotec, which could potentially enhance its product portfolio.
The exclusive global license agreement with Evotec allows Bristol Myers Squibb to potentially enhance its product portfolio. This could lead to increased revenues and profitability in the future, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Evotec has entered into an exclusive global license agreement with Bristol Myers Squibb, which could potentially increase its revenues.
The exclusive global license agreement with Bristol Myers Squibb allows Evotec to potentially increase its revenues. This could lead to increased profitability in the future, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100